Cardio Diagnostics Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cardio Diagnostics Hldgs (CDIO).

Price Target Range — 2 Quarters

Analyst Consensus

Consensus RatingSpeculative BuyAvg. Consensus PT$60Upside to Avg. PT+3309.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 27, 2024	Benchmark	Bruce Jackson	Maintained	Speculative Buy	$2
Jun 6, 2024	Benchmark	Bruce Jackson	PT Raise	Speculative Buy	$1→$2
Apr 19, 2024	Benchmark	Bruce Jackson	PT Cut	Speculative Buy	$4→$1

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Benchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $2 Price Target

Benchmark analyst Bruce Jackson reiterates Cardio Diagnostics Hldgs (NASDAQ:CDIO) with a Speculative Buy and maintains $2 price target.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Raises Price Target to $2

Benchmark analyst Bruce Jackson maintains Cardio Diagnostics Hldgs (NASDAQ:CDIO) with a Speculative Buy and raises the price target from $1.35 to $2.

Benzinga Newsdesk

PRO
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Lowers Price Target to $1.35

Benchmark analyst Bruce Jackson maintains Cardio Diagnostics Hldgs (NASDAQ:CDIO) with a Speculative Buy and lowers the price target from $4 to $1.35.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $8 Price Target

Benchmark analyst Bruce Jackson reiterates Cardio Diagnostics Hldgs (NASDAQ:CDIO) with a Speculative Buy and maintains $8 price target.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023

Benzinga Insights

PRO
Northland Capital Markets Initiates Coverage On Cardio Diagnostics Hldgs with Outperform Rating, Announces Price Target of $8

Northland Capital Markets analyst Carl Byrnes initiates coverage on Cardio Diagnostics Hldgs (NASDAQ:CDIO) with a Outperform rating and announces Price Target of $8.

Benzinga Newsdesk

Cardio Diagnostics Holdings Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Cardio Diagnostics Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Benchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $2 Price Target

PRO
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Raises Price Target to $2

PRO
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Lowers Price Target to $1.35

PRO
Benchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $8 Price Target

Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023

PRO
Northland Capital Markets Initiates Coverage On Cardio Diagnostics Hldgs with Outperform Rating, Announces Price Target of $8

People Also Watch

People Also Watch

Cardio Diagnostics Holdings Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Cardio Diagnostics Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBenchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $2 Price Target

PROBenchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Raises Price Target to $2

PROBenchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Lowers Price Target to $1.35

PROBenchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $8 Price Target

Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023

PRONorthland Capital Markets Initiates Coverage On Cardio Diagnostics Hldgs with Outperform Rating, Announces Price Target of $8

People Also Watch

People Also Watch

PRO
Benchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $2 Price Target

PRO
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Raises Price Target to $2

PRO
Benchmark Maintains Speculative Buy on Cardio Diagnostics Hldgs, Lowers Price Target to $1.35

PRO
Benchmark Reiterates Speculative Buy on Cardio Diagnostics Hldgs, Maintains $8 Price Target

PRO
Northland Capital Markets Initiates Coverage On Cardio Diagnostics Hldgs with Outperform Rating, Announces Price Target of $8